This company has been acquired
Cerevel Therapeutics Holdings Management
Management criteria checks 2/4
Cerevel Therapeutics Holdings' CEO is Ron Renaud, appointed in Jun 2023, has a tenure of 1.17 years. total yearly compensation is $32.32M, comprised of 1.2% salary and 98.8% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $10.98M. The average tenure of the management team and the board of directors is 3.7 years and 5.4 years respectively.
Key information
Ron Renaud
Chief executive officer
US$32.3m
Total compensation
| CEO salary percentage | 1.2% |
| CEO tenure | 1.2yrs |
| CEO ownership | 0.1% |
| Management average tenure | 3.7yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?
Apr 30
Cerevel overweight at Wells Fargo due to candidates with blockbuster potential
Sep 26Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering
Aug 12Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13
Aug 01Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded
Jul 08Cerevel Therapeutics: Pfizer's Neurology Spin-Off
Jul 14Cerevel Therapeutics (CERE) Investor Presentation - Slideshow
Nov 18Cerevel Therapeutics reports Q3 results
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$460m |
| Dec 31 2023 | US$32m | US$375k | -US$433m |
Compensation vs Market: Ron's total compensation ($USD32.32M) is above average for companies of similar size in the US market ($USD8.50M).
Compensation vs Earnings: Insufficient data to compare Ron's compensation with company performance.
CEO
Ron Renaud (55 yo)
1.2yrs
Tenure
US$32,322,358
Compensation
Mr. Ronald C. Renaud, also known as Ron, Jr., M.B.A., serves as President, CEO & Director at Cerevel Therapeutics Holdings, Inc. since June 12, 2023. He served as Managing Director at Bain Capital Life Sci...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 5.8yrs | US$31.98m | 0.0086% $ 702.8k | |
| President | 1.2yrs | US$32.32m | 0.13% $ 11.0m | |
| Chief Financial Officer | 1.3yrs | US$4.63m | 0.0093% $ 760.2k | |
| Senior VP of Finance & Chief Accounting Officer | 4.9yrs | US$1.21m | 0.0097% $ 797.0k | |
| Chief Scientific Officer | 5.3yrs | US$3.45m | 0.0035% $ 286.7k | |
| Chief Medical Officer | 5.6yrs | US$4.13m | 0.0080% $ 659.4k | |
| Chief Business Development & Strategic Operations Officer | 1.2yrs | US$3.55m | 0.025% $ 2.1m | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 3.3yrs | US$3.19m | 0.0040% $ 325.2k | |
| Chief Human Resources Officer | 5.3yrs | no data | 0.014% $ 1.1m | |
| Chief Corporate Affairs Officer & Head of Commercial Strategy | 4.1yrs | US$3.92m | 0.0059% $ 479.2k |
3.7yrs
Average Tenure
54yo
Average Age
Experienced Management: CERE's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 5.8yrs | US$31.98m | 0.0086% $ 702.8k | |
| President | 1.2yrs | US$32.32m | 0.13% $ 11.0m | |
| Independent Director | 5.2yrs | US$513.93k | 0.027% $ 2.2m | |
| Independent Director | 5.9yrs | US$486.49k | 0.017% $ 1.4m | |
| Independent Director | 3.6yrs | US$485.48k | 0.0018% $ 147.4k | |
| Lead Independent Director | 5.7yrs | US$564.65k | 0.025% $ 2.1m | |
| Independent Director | 5.9yrs | US$501.43k | 0.0018% $ 147.4k | |
| Independent Director | 5.9yrs | US$504.65k | 0.0018% $ 147.4k | |
| Independent Director | 5.9yrs | US$505.21k | 0.0018% $ 147.4k | |
| Independent Director | 3.7yrs | US$485.48k | 0% $ 0 | |
| Independent Director | 2.2yrs | no data | no data | |
| Independent Director | 3.6yrs | no data | no data |
5.4yrs
Average Tenure
62.5yo
Average Age
Experienced Board: CERE's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/04 20:26 |
| End of Day Share Price | 2024/08/02 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cerevel Therapeutics Holdings, Inc. is covered by 16 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Esther Lannie Hong | Berenberg |
| Tazeen Ahmad | BofA Global Research |